Glembatumumab vedotin is an antibody–drug conjugate derived from dolastatin 10 that targets transmembrane glycoprotein NMB (GPNMB) in GPNMB-positive metastatic triple-negative breast cancer [281]. Here, GPNMB is linked to triple-negative breast carcinoma.